RTP Mobile Logo
Select Publications

Facon T et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2021;137(26):3616-28. Abstract

Manda S et al. Feasibility of long-term proteasome inhibition in multiple myeloma by in-class transition from bortezomib to ixazomib. Clin Lymphoma Myel Leuk 2020;20(11)e910-25. Abstract

Mateos M-V et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018;378(6):518-28. Abstract

Moreau P et al. Treatment of relapsed and refractory multiple myeloma: Recommendations from the International Myeloma Working Group. Lancet Oncol 2021;22(3):e105-18. Abstract

Paiva B et al. Measurable residual disease (MRD) evaluation during ixazomib (ixa) maintenance in newly diagnosed multiple myeloma (NDMM): A large analysis of 1280 patients (pts) enrolled in TOURMALINE-MM3 and -MM4. ESMO 2021;Abstract S184.

Usmani SZ et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): Primary analysis of a randomised, phase 2 trial. Lancet Haematol 2021;8(1):e45-54. Abstract